Differential Response Of Breast Carcinoma To Epidermal Growth Factor Receptor Inhibitors

Until recently, the molecular mechanisms underlying the sensitivity of tyrosine kinase inhibitors remained unknown. Paradoxical associations between EGFR expression and response to treatment lead to further confusion regarding determinants of response to therapy. Recently demonstrated in nonsmall cell lung cancer was the observation that specific mutations in the EGFR tyrosine kinase domain predicted for response to treatment with agents that block EGFR receptors. Two separate study groups (98,99) reported the discovery and the identification of missense and deletion mutations that cause the EGFR to have a much higher affinity for gefitinib and hence lead to an increased responsiveness to the tyrosine kinase inhibitor. Recently reported were the results of Lee et al. (100) who investigated the presence of somatic mutations of ErbB2 kinase domain in gastric, colorectal, and breast carcinomas. The authors concluded that in addition to lung adeno-carcinomas, ErbB2 kinase domain mutations occur in breast cancers in addition to other cancers.

Quit Smoking For Good

Quit Smoking For Good

Quit smoking for good! Stop your bad habits for good, learn to cope with the addiction of cigarettes and how to curb cravings and begin a new life. You will never again have to leave a meeting and find a place outside to smoke, losing valuable time. This is the key to your freedom from addiction, take the first step!

Get My Free Ebook

Post a comment